Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950

British Journal of Pharmacology

Volumn 118, Issue 3, 1996, Pages 711-719

  Hilditch, A ^a   Prior, Helen M ^b,c   Drew, G M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Angiotensin AT1 receptor antagonist; Angiotensin AT1 receptors; Angiotensin I; Angiotensin II; Blood pressure; Conscious rats; Enalapril; GR138950; Hypertensive rats; Rat isolated aorta

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANTIHYPERTENSIVE AGENT; ENALAPRIL; SAPRISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029982378     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15458.x     Document Type: Article

References (20)

1. AKERS, J.S., HILDITCH, A., ROBERTSON, M.J. & DREW, G.M. (1991). Does a relationship exist between the antihypertensive action and the angiotensin receptor antagonist activity of DuP753 in conscious rats? Br. J. Pharmacol., 104, 126P
2. CALDWELL, P.R.B., SEEGEL, B.C., HSU, K.C., DAS, M. & SOFFER, R.L. (1976). Angiotensin converting enzyme: vascular endothelial localisation. Science, 191, 1050-1051.
3. CAMPBELL, D.J. (1993). Metabolism of prorenin, renin, angiotensinogen, and the angiotensins by tissues. In The Renin-Angiotensin System: ed. Robertson, J.I. & Nicholls, M.G. pp. 23.1-23.23. London: Gower Medical Publishing.
4. CAMPBELL, D.J., ZIOGAS, J. & KLADIS, A. (1990). Metabolism of tetradecapeptide, angiotensinogen and angiotensin I and II by isolated perfused rat hindlimb. Clin. Exp. Pharmacol. Physiol., 17, 335-350.
5. CANGIANO, J.L., RODRIGUEZ-SARGENT, C. & MARTINEZ-MALDONADO, M. (1979). Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats. J. Pharmacol. Exp. Ther., 208, 310-313.
6. CHIU, A.T., MCCALL, D.E., PRICE, W.A., WONG, P.C., CARINI, D.J., DUNCIA, J.V., WEXLER, R.R., YOO, S.E., JOHNSON, A.L. & TIMMERMANS, P.B.M.W.M. (1990). Non-peptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 252, 711-718.
7. DREW, G.M. (1993). Differences between angiotensin II antagonists. In Current Advances in ACE Inhibition 3. ed. McGreggor, G.A., Sever, P., Caldwell, D. & Menard, J. pp. 92-97, London: Churchill Livingstone.
8. DZAU, V.J. (1987). Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am. J. Cardiol., 59, 59A-65A.
9. EGLÈME, C., CRESSIER, F. & WOOD, J.M. (1990). Local formation of angiotensin II in the rat aorta: effect of endothelium. Br. J. Pharmacol., 100, 237-240.
10. FURCHGOTT, R.F. & ZAWADSKI, J. V. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288, 373-376.
11. GRUETTER, C.A., RYAN, E.T., LEMKE, S.M., BAILLY, D.A., FOX, M.K. & SCHOEPP, D.D. (1988). Endothelium-dependent modulation of angiotensin II-induced contraction in blood vessels. Eur. J. Pharmacol., 146, 85-95.
12. 1 receptor antagonist. Br. J. Pharmacol., 111, 137-144.
13. 1 receptor antagonist. Br. J. Pharmacol., 109, 239P.
14. 1 receptor antagonist. J. Pharmacol. Exp. Ther., 272, 750-757.
15. JUDD, D.B., DOWLE, M.D., MIDDLEMISS, D., SCOPES, D.I., ROSS, B.C., JACK, T.I., PASS, M., TRANQUILLINI, E., HOBSON, J.E., PANCHAL, T.A., STUART, P.G., PATON, J.M.S., HUBBARD, T., HILDITCH, A., DREW, G.M., ROBERTSON, M.J., CLARK, K.L., TRAVERS, A., HUNT, A.A.E., POLLEY, J., EDDERSHAW, P.J., BAYLISS, M.K., MANCHEE, G.R., DONNELLY, M.D., WALKER, D.G. & RICHARDS, S.A. (1994). Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability. J. Med. Chem., 37, 3108-3120.
16. KIFOR, I. & DZAU, V.C. (1987). Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. Circ. Res., 60, 422-428.
17. OHLSTEIN, E.H., GELLAI, M., BROOKS, D.P., VICKERY, L., JUGUS, J., SULPIZIO, A., RUFFOLO, R.R., WEINSTOCK, J. & EDWARDS, R.M. (1992). The antihypertensive effect of the angiotensin II antagonist DuP753 may not be due solely to angiotensin II receptor antagonism. J. Pharmacol. Exp. Ther., 262, 595-601.
18. 1, antagonism. J. Pharmacol. Exp. Ther., 273, 753-761.
19. 1 receptor antagonist, GR138950. Br. J. Pharmacol., 115, 56P.
20. TRAVERS, A. & HILDITCH, A. (1992). Temporal involvement of the renin-angiotensin system in hypertension produced by left renal artery ligation in conscious rats. Br. J. Pharmacol., 105, 197P.